FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 15:38:24 2024-05-15 EDT | ||
| 2 EUR | -8.68% |
|
| Current month | -36.91% | ||
| 1 month | -35.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
| Date | Price | Change |
|---|---|---|
| 24-05-15 | 2 | -8.68% |
| 24-05-14 | 2.19 | +0.46% |
| 24-05-13 | 2.18 | -7.23% |
| 24-05-10 | 2.35 | -2.49% |
| 24-05-09 | 2.41 | +1.69% |
Delayed Quote Börse Stuttgart
Last update May 15, 2024 at 03:38 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK2LTX |
| ISIN | DE000JK2LTX1 |
| Date issued | 2024-02-23 |
| Strike | 535.7 $ |
| Maturity | Unlimited |
| Parity | 46.71 : 1 |
| Emission price | 2.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.35 € |
|---|---|
| Lowest since issue | 2 € |
| Spread | 0.09 € |
| Spread % | 4.33% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
437.5
USD
Average target price
462.6
USD
Spread / Average Target
+5.73%
- Stock Market
- Certificates
- Certificat